BridgeBio is demonstrably boosted its course of the innovative treatment for ATTR-CM, leveraging the investigational drug. Preliminary patient results suggests promising outcomes for individuals suffering by a serious https://biotech386590.livebloggs.com/48919376/firm-advances-cardiac-amyloidosis-therapy-through-attruby